OBJECTIVE: To evaluate serum levels of CXCL10 and CCL2 in a large series of PsA patients, and to relate chemokines levels to the clinical phenotype of these patients. METHODS: Serum levels of CXCL10 and CCL2 were measured in 68 PsA patients, and in gender- and age-matched (1:1) controls drawn from the general population. RESULTS: PsA patients showed significantly (p<0.001) higher mean CXCL10 serum levels than controls (p<0.0001), (269+/-234 vs. 92+/-53 pg/ml; respectively). By defining a high CXCL10 level as a value at least 2 SD above the mean value of the control group (>198 pg/ml), 49% of patients with PsA and 5% of the control subjects had high CXCL10 (p<0.0001; chi-square). A significant inverse correlation was observed between CXCL10 serum levels and disease duration (r= 0.374, p=0.002).Patients with PsA showed significantly higher mean CCL2 serum levels than controls (p<0.001), (512+/-309 vs. 386+/-172, pg/ml; respectively). By defining a high CCL2 level as a value at least 2 SD above the mean value of the control group (>730 pg/ml), 19% of patients with PsA, 2% of the control subjects had high CCL2 (p<0.001; chi-square=22.02). CONCLUSION: In conclusion, high circulating levels of CXCL10 and CCL2 have been found in PsA patients, with a Th1 immune predominance in the early phase of the disease. A decline of CXCL10 levels has been observed in long lasting PsA, with a significant increase of the CCL2/CXCL10 ratio, suggesting a shift from Th1 to Th2 immune response in long duration PsA.
OBJECTIVE: To evaluate serum levels of CXCL10 and CCL2 in a large series of PsA patients, and to relate chemokines levels to the clinical phenotype of these patients. METHODS: Serum levels of CXCL10 and CCL2 were measured in 68 PsA patients, and in gender- and age-matched (1:1) controls drawn from the general population. RESULTS: PsA patients showed significantly (p<0.001) higher mean CXCL10 serum levels than controls (p<0.0001), (269+/-234 vs. 92+/-53 pg/ml; respectively). By defining a high CXCL10 level as a value at least 2 SD above the mean value of the control group (>198 pg/ml), 49% of patients with PsA and 5% of the control subjects had high CXCL10 (p<0.0001; chi-square). A significant inverse correlation was observed between CXCL10 serum levels and disease duration (r= 0.374, p=0.002).Patients with PsA showed significantly higher mean CCL2 serum levels than controls (p<0.001), (512+/-309 vs. 386+/-172, pg/ml; respectively). By defining a high CCL2 level as a value at least 2 SD above the mean value of the control group (>730 pg/ml), 19% of patients with PsA, 2% of the control subjects had high CCL2 (p<0.001; chi-square=22.02). CONCLUSION: In conclusion, high circulating levels of CXCL10 and CCL2 have been found in PsA patients, with a Th1 immune predominance in the early phase of the disease. A decline of CXCL10 levels has been observed in long lasting PsA, with a significant increase of the CCL2/CXCL10 ratio, suggesting a shift from Th1 to Th2 immune response in long duration PsA.
Authors: Kun-Yu Teng; Jianfeng Han; Xiaoli Zhang; Shu-Hao Hsu; Shun He; Nissar A Wani; Juan M Barajas; Linda A Snyder; Wendy L Frankel; Michael A Caligiuri; Samson T Jacob; Jianhua Yu; Kalpana Ghoshal Journal: Mol Cancer Ther Date: 2016-12-15 Impact factor: 6.261
Authors: Li Dong; Xiao Ying Lv; Bin Jie Wang; Ye Qing Wang; Hua Mu; Zhuo Lei Feng; Ping Liu Journal: Graefes Arch Clin Exp Ophthalmol Date: 2014-05-09 Impact factor: 3.117
Authors: Adele Hannigan; Asif M Qureshi; Colin Nixon; Penelope M Tsimbouri; Sarah Jones; Adrian W Philbey; Joanna B Wilson Journal: Mol Cancer Date: 2011-02-03 Impact factor: 27.401
Authors: Ruili Guan; Sharad Purohit; Hongjie Wang; Bruce Bode; John Chip Reed; R Dennis Steed; Stephen W Anderson; Leigh Steed; Diane Hopkins; Chun Xia; Jin-Xiong She Journal: PLoS One Date: 2011-04-12 Impact factor: 3.240